David M. Madden

Dave is Founder and Principal of Narrow River Management, LP, a company engaged in drug licensing and development. From 2011 through 2017, he was CEO of River Vision Development Corp., an entity formed and managed by Narrow River for the development of teprotumumab for thyroid eye disease and sold to Horizon Pharma in 2017. Prior to founding Narrow River, Dave was Chairman and interim CEO of Adolor Corp. until its sale to Cubist Pharmaceuticals in 2011. He was the Co-CEO of Royalty Pharma, a company engaged in buying drug royalties, from 1997-2003. Prior to that he was CEO of Selectide Corp., a combinatorial chemistry-based drug discovery company sold to Marion Merrell Dow in 1995. Dave started his career at PaineWebber Development Corp in 1987, leaving in 1992 to join Selectide as its CEO. He was Chairman of Dicerna Pharmaceuticals from 2009-2019 and served on the board of Trustees of the Hospital for Special Surgery from 2004-2016.

Dave received a BSEE in Electrical Engineering from Union College and an MBA from Columbia University.